September 8, 2022

CEO Ulf Jungnelius speaks with Redeye
in connection to the new reported data
from the Phase III AGENT study

Listen to the interview if you are an investor, analyst or work with media >>

Audiocast, August 23, 2022

Isofol held a presentation in conjunction
with the publication of the interim report
for the second quarter of 2022

Listen to the audiocast again if you are an investor, analyst or works with media >>



Startpage 3

This website is intended for use by residents of Sweden only

About Isofol

Isofol Medical AB (publ) is a biotech company that was founded in 2008 and is developing a new drug candidate for the treatment of advanced colorectal cancer. Colorectal cancer (CRC) is the third most common form of cancer worldwide and the need for more effective drugs to treat this disease is very high.


Upcoming Events

  • November 11, 2022 - November 11, 2022
    Interim Report Q3 2022
  • February 23, 2023 - February 23, 2023
    Year-end Report 2022